Friday, 17 Nov 2017

You are here

8 September 2017: The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report includes trends in MTX use and outcomes, fibromyalgia as an inflammatory disorder, drugs that stop psoriasis pruritus, drugs that don't cause TB, cardiovascular risk and what Rheums think of ACR/EULAR criteria.

  1. 192 Chronic fatigue patient show high TGF-B,low resistin, 17 cytokines correlate with activity(CXCL*, GF, IL-4, IL5, IL7, IL13, IL17F, several growth factors. https://buff.ly/2xa8A8k 
  2. Between 2004-2014, MTX use increased (40% to 64%) and biologic use increased (from to1.7% to 27%), but the rate of ortho hip and knee surgery dropped (72 to 51/1000pts in 2014) https://t.co/IE72n2YMPB
  3. Optimal MTX dosing in early #RA patients (≥10mg/wk w/in 3 mos and ≥20mg/wk @6mo) improves clinical & functional but not Xray outcomes https://t.co/dJQjFrub4Q
  4. A review of 230 SLE patients, 95 had both abnormal protein-creatinine ratio (PCR) AND a 24 Hr Protein measures; serial assessments showed PCR had insufficient accuracy vs 24hr-Prot measures https://t.co/UjtoRagWAF
  5. Base on claims data, prevalence of RA increased over 10 yr period; RA found in 1.28-1.36 million adults (or roughly 0.5%) by 2014 https://t.co/t5GwPsifIC
  6. Psoriasis pruritus seen in >80%; metaanalysis 13 trials shows Anti Il-17, JAK inhib, ADA, apremilast reduce pruritus https://t.co/KXbZxLizD0 
  7. Despite the FDA requiring TB testing for IL-17 inhibitors; no reported TB cases in 1st Yr RCTs and in vitro studies show no mTB reactivation with IL17inhibition  https://t.co/7A7fRUyaLN
  8. 167 RA patients that were serially assessed over 2 yrs; only BMD loss by DXA predicted Xray damage @ 12 & 24 mos; NOT DAS, RF, CCP, or ESR https://t.co/u6D6nJdKvx
  9. Study of 153K RA patients, 23% had Anemia,and review of their drugs found that anemia was only improved by tocilizumab, not with Tofa, DMARDs, other biologics. https://t.co/UY0DgU2usb
  10. New Recommendations on Biosimilar Use   
  11. Rheumatoid Arthritis Augments Cardiovascular Risk   
  12. Increasing Deaths and Breaking Bad with Fentanyl   
  13. Do Rheumatologists Use ACR/EULAR Guidance on Rheumatoid Arthritis? “Live Vote” Results   
  14. Hugo E. Jasin, MD (1933-2017)   
Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

The RheumNow Week in Review - 17 November 2017

Dr. Jack Cush reviews the news and highlights from the past week on RheumNow.com. This week he covers FDA warnings on gout drugs, steroid use in Australia, biosimilars lost savings and methotrexate hepatotoxicity in psoriatic arthritis (PsA).

Podcast of ACR17 - Day 4

Care to learn what you missed at last weeks ACR 2017 meeting in San Diego?  Here are 4 one hour audio podcasts - each with a compliation of 2-4 minute reports from Drs. Cush, Kavanaugh, the RheumNow Faculty and other rheumatology thought leaders and researchers.  Another good way to learn from RheumNow.

The ACR17 RheumNow Week in Review - 10 November 2017

This special edition of the RheumNow Week in Review covers highlights of selected sessions from the 2017 ACR annual meeting in San Diego. Dr. Jack Cush reviews lupus and the microbiome, daily podcasts, pregnancy and lactation, osteoporosis drug holidays and screening for pulmonary hypertension.

Many thanks to the RheumNow Faculty for their work and expertise!

Podcast of ACR 17 - Day 3

Check out this compilation of our ACR17 Day 3 broadcasts, merged into a single one hour podcast !

ACR 2017 - Day 3 and 4 Highlights

Day 3 at the annual meeting was rich with information. Yet the most anticipated and best attended session was the Late Breaking Abstracts and the session revealing the new ACR/NPF Guidelines for Psoriatic Arthritis (more on the latter in another report).  Day 4 was full of review sessions and a modicum of original content and for me, the 7:30AM Rheumatology Roundup.